H e m a t o lo g y E d u c a t io n - European Hematology Association
H e m a t o lo g y E d u c a t io n - European Hematology Association
H e m a t o lo g y E d u c a t io n - European Hematology Association
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
16 th Congress of the <strong>European</strong> Hemato<strong>lo</strong>gy Associat<strong>io</strong>n<br />
15. Branehog I, Kutti J, Weinfeld A. (1974) Platelet survival and<br />
platelet product<strong>io</strong>n in id<strong>io</strong>pathic thrombocytopenic purpura<br />
(ITP). Br J Haematol. 1974;27:127-43.<br />
16. Harker LA. Thrombokinetics in id<strong>io</strong>pathic thrombocytopenic<br />
purpura. Br J Haematol. 1970;19:95-104.<br />
17. Harker LA, Finch CA. Thrombokinetics in man. J Clin Invest.<br />
1969;48:963-74.<br />
18. Ballem PJ, Segal GM, Stratton JR, Gernsheimer T, Adamson<br />
JW, Slichter SJ. Mechanisms of thrombocytopenia in chronic<br />
autoimmune thrombocytopenic purpura. Evidence of both<br />
impaired platelet product<strong>io</strong>n and increased platelet clearance.<br />
J Clin Invest. 1987;80:33-40<br />
19. Heyns AdP, Badenhorst PN, Lotter MG, Pieters H, Wessels P,<br />
Kotze HF. Platelet turnover and kinetics in immune thrombocytopenic<br />
purpura: results with auto<strong>lo</strong>gous 111In-labeled<br />
platelets and homo<strong>lo</strong>gous 51Cr-labeled platelets differ. B<strong>lo</strong>od.<br />
1986;67:86-92.<br />
20. Stoll D, Cines DB, Aster RH, Murphy S. (1985) Platelet kinetics<br />
in patients with id<strong>io</strong>pathic thrombocytopenic purpura and<br />
moderate thrombocytopenia. B<strong>lo</strong>od. 1985;65:584-88.<br />
21. Li Z, Nardi MA, Karpatkin S. Role of molecular mimicry to<br />
HIV-1 peptides in HIV-1-related immuno<strong>lo</strong>gic thrombocytopenia.<br />
B<strong>lo</strong>od. 2005;106:572–6.<br />
22. Zhang W, Nardi MA, Borkowsky W, et al. Role of molecular<br />
mimicry of hepatitis C virus protein with platelet GPIIIa in<br />
hepatitis C-related immuno<strong>lo</strong>gic thrombocytopenia. B<strong>lo</strong>od.<br />
2009;113:4086-93.<br />
23. Takahashi T, Yujiri T, Shinohara K, et al. Molecular mimicry<br />
by Helicobacter py<strong>lo</strong>ri CagA protein may be involved in the<br />
pathogenesis of H. py<strong>lo</strong>ri-associated chronic id<strong>io</strong>pathic<br />
thrombocytopenic purpura. Br J Haematol. 2004;124:91-6.<br />
24. Cines DB, Liebman H, Stasi R. Pathob<strong>io</strong><strong>lo</strong>gy of secondary<br />
immune thrombocytopenia. Semin Hematol. 2009;46:S2-14.<br />
25. Cines DB. Pathogenesis of ITP. In Cines DB, Kuter DJ,<br />
Newland AC, Provan D, Semple, JW, editors. Immune<br />
Thrombocytopenia: The Handbook. 2011ESH Forum Service<br />
Editore. P. 77-89<br />
26. Mazzucconi NG, Fazi P, Bernasconi S, et al. Therapy with<br />
high-dose dexamethasone (HDDXM) in prev<strong>io</strong>usly untreated<br />
patients affected by id<strong>io</strong>pathic thrombocytopenic purpura. A<br />
GIMEMA experience. B<strong>lo</strong>od. 2007;109:1401-7.<br />
27. Psaila B, Bussel J. Refractory id<strong>io</strong>pathic thrombocytopenic purpura:<br />
current strategies for investigat<strong>io</strong>n and management. Br<br />
J Haematol. 2008;143:16-26.<br />
28. Provan D, Moss AJ, Newland AC, Bussel JB. Efficacy of<br />
mycophenolate mofetil as single-agent therapy for refractory<br />
immune thrombocytopenic purpura. Am J Hematol. 2006<br />
Jan;81(1):19-25.<br />
29. Portielje JE, Westendorp RG, Kluin-Nelemans HC, Brand A.<br />
Morbidity and mortality in adults with id<strong>io</strong>pathic thrombocytopenic<br />
purpura. B<strong>lo</strong>od. 2001;97:2549-54.<br />
30. Stasi R, Stipa E, Masi M, et al. Long-term observat<strong>io</strong>n of 208<br />
adults with chronic id<strong>io</strong>pathic thrombocytopenic purpura.<br />
Am J Med. 1995;98:436-42.<br />
31. Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric<br />
anti-CD20 monoc<strong>lo</strong>nal antibody treatment for adults with<br />
chronic id<strong>io</strong>pathic thrombocytopenic purpura. B<strong>lo</strong>od. 2001;<br />
98:952-7.<br />
32. Arnold DM, Dentali F, Crowther MA, et al. Systematic review:<br />
Efficacy and safety of rituximab for adults with id<strong>io</strong>pathic thrombocytopenic<br />
purpura. Ann Intern Med. 2007;146:25-33.<br />
33. Cooper N, Stasi R, Cunningham-Rundles S, et al. The efficacy<br />
and safety of B-cell deplet<strong>io</strong>n with anti-CD20 monoc<strong>lo</strong>nal<br />
antibody in adults with chronic immune thrombocytopenic<br />
purpura. Br J Haematol. 2004;125:232-239.<br />
34. Godeau B, Porcher R, Fain O, et al. Rituximab efficacy and<br />
safety in adult splenectomy candidates with chronic immune<br />
thrombocytopenic purpura - results of a prospective multicenter<br />
phase 2 study. B<strong>lo</strong>od. 2008;112:999-1004.<br />
35. Zaja F, Baccarani M, Mazza P, et al. Dexamethasone plus rituximab<br />
yields higher sustained response rates than dexamethasone<br />
monotherapy in adults with primary immune<br />
thrombocytopenia. B<strong>lo</strong>od. 2010 Feb 3. [Epub ahead of print as<br />
doi: 10.1182/b<strong>lo</strong>od-2009-07-229815].<br />
36. Zaja F, Vianelli N, Volpetti S, et al. Low-dose rituximab in adult<br />
patients with primary immune thrombocytopenia. Eur J<br />
Haematol. 2010 Jun 10. [Epub ahead of print as doi:].<br />
37. Provan D, Butler T, Evangelista ML, et al. Activity and safety<br />
profile of <strong>lo</strong>w-dose rituximab for the treatment of autoimmune<br />
cytopenias in adults. Haemato<strong>lo</strong>gica. 2007;92:1695-8.<br />
38. Carson KR, Focosi D, Major EO, et al. Monoc<strong>lo</strong>nal antibodyassociated<br />
progressive multifocal leucoencepha<strong>lo</strong>pathy in<br />
patients treated with rituximab, natalizumab, and efalizumab:<br />
A Review from the Research on Adverse Drug Events and<br />
Reports (RADAR) Project. Lancet Oncol. 2009;10:816-24.<br />
39. Gottenberg J, Ravaud P, Bardin T, et al. Risk factors of severe<br />
infect<strong>io</strong>ns in patients with rheumatoid arthritis treated with<br />
rituximab in the AutoImmunity and Rituximab (AIR) registry.<br />
Arthritis Rheum. 2010;62:2625-32.<br />
40. Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for<br />
adult patients with id<strong>io</strong>pathic thrombocytopenic purpura: A<br />
systematic review to assess <strong>lo</strong>ng-term platelet count responses,<br />
predict<strong>io</strong>n of response, and surgical complicat<strong>io</strong>ns. B<strong>lo</strong>od.<br />
2004;104:2623-34.<br />
41. Wanachiwanawin W, Visudhiphan S, Pinankijagum A,<br />
Vatanavicharn S. Therapy of chronic id<strong>io</strong>pathic thrombocytopenic<br />
purpura in adults: Experiences from Thailand. Southeast<br />
Asian J Trop Med Public Health. 1993;24(Suppl 1):71-5.<br />
42. Robinette CD, Fraumeni JF. Splenectomy and subsequent mortality<br />
in veterans of the 1939-45 war. Lancet .1977;ii:127-9.<br />
43. Bisharat N, Omari H, Lavi I, Raz R. Risk of infect<strong>io</strong>n and death<br />
among post-splenectomy patients. J Infect. 2001;43:182-6.<br />
44. Schwartz J, Leber MD, Gillis S, et al. Long term fol<strong>lo</strong>w-up<br />
after splenectomy performed for immune thrombocytopenic<br />
purpura (ITP). Am J Hematol. 2003;72:94-8.<br />
45. McMillan R, Wang L, Tomer A, Nichol J, Pistil<strong>lo</strong> J. Suppress<strong>io</strong>n<br />
of in vitro megakaryocyte product<strong>io</strong>n by antiplatelet autoantibodies<br />
from adult patients with chronic ITP. B<strong>lo</strong>od.<br />
2004;103:1364-1369.<br />
46. Olsson B, Andersson PO, Jernas M, et al. T-cell-mediated cytotoxicity<br />
toward platelets in chronic id<strong>io</strong>pathic thrombocytopenic<br />
purpura. Nat Med. 2003;9:1123-4.<br />
47. Yu J, Heck S, Patel V, et al. Defective circulating CD25 regulatory<br />
T cells in patients with chronic immune thrombocytopenic<br />
purpura. B<strong>lo</strong>od. 2008;112:1325-8.<br />
48. Sarpatwari A, Provan D, Erquo S, Sobnack R, Tai FWD,<br />
Newland AC. Auto<strong>lo</strong>gous 111 In-labelled platelet sequestrat<strong>io</strong>n<br />
studies in patients with primary immune thrombocytopenia<br />
(ITP) pr<strong>io</strong>r to splenectomy: a report from the United<br />
Kingdom ITP Registry. Br J Haematol. 2010;151:477-87.<br />
49. Molineux G, Newland A. Deve<strong>lo</strong>pment of romip<strong>lo</strong>stim for the<br />
treatment of patients with chronic immune thrombocytopenia:<br />
from bench to bedside. Br J Haematol. 2010;150:9-20.<br />
50. Newland, A. Thrombopoietin mimetic agents in the management<br />
of immune thrombocytopenic purpura. Semin Hematol.<br />
2007;44:35-45.<br />
51. Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romip<strong>lo</strong>stim<br />
in patients with chronic immune thrombocytopenic purpura:<br />
a double blind randomized controlled trial. Lancet. 2008 Feb<br />
2;371(9610):395-403.<br />
52. Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL.<br />
Safety and Efficacy of <strong>lo</strong>ng-term treatment with romip<strong>lo</strong>stim in<br />
thrombocytopenic patients with ITP. B<strong>lo</strong>od. 2009;113:2161-71.<br />
53. Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for the<br />
management of chronic immune thrombocytopenia (RAISE):<br />
a 6 month, randomised phase 3 study. Lancet. 2011 Jan<br />
29;377(9763):393-402. Erratum in: Lancet. 2011 Jan 29;377<br />
(9763):382.<br />
54. Sarpatwari A, Bennett D, Logie JW, Shukla A, Beach KJ,<br />
Newland AC. Thromboembolic events among adult patients<br />
with primary immune thrombocytopenia in the United<br />
Kingdom General Practice Research Database. Haemato<strong>lo</strong>gica.<br />
2010;95:1167-75.<br />
55. Li X, Hou M. Emerging drugs for id<strong>io</strong>pathic thrombocytopenic<br />
purpura in adults. Expt Opin Emerg Drugs. 2008;13:237-54.<br />
56. Podolanczuk A, Lazarus AH, Crow AR, Grossbard E, Bussel<br />
JB. Of mice and men: an open-label pi<strong>lo</strong>t study for treatment<br />
of immune thrombocytopenic purpura by an inhibitor of Syk.<br />
B<strong>lo</strong>od. 2009;113:3154-60.<br />
57. Newland AC. Future managements of ITP; in Immune<br />
Thrombocytopenia: The Handbook. Cines DB, Kuter DJ,<br />
Newland AC, Provan D, Semple JW, editors.2011. ESH Forum<br />
Service Editore P. 227-242.<br />
| 190 | Hemato<strong>lo</strong>gy Educat<strong>io</strong>n: the educat<strong>io</strong>n programme for the annual congress of the <strong>European</strong> Hemato<strong>lo</strong>gy Associat<strong>io</strong>n | 2011; 5(1)